(Q39682105)

English

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors

scientific article published on March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

retracted paper

1 reference

Retraction Watch

29 December 2023

https://doi.org/10.1016/j.lungcan.2023.107226

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors (English)

1 reference

Europe PubMed Central

13 September 2017

Fortunato Ciardiello

9

object named as

Fortunato Ciardiello

1 reference

Europe PubMed Central

13 September 2017

author name string

Floriana Morgillo

1

1 reference

Europe PubMed Central

13 September 2017

Elena D'Aiuto

2

1 reference

Europe PubMed Central

13 September 2017

Teresa Troiani

3

1 reference

Europe PubMed Central

13 September 2017

Erika Martinelli

4

1 reference

Europe PubMed Central

13 September 2017

Tina Cascone

5

1 reference

Europe PubMed Central

13 September 2017

Raffaele De Palma

6

1 reference

Europe PubMed Central

13 September 2017

Michele Orditura

7

1 reference

Europe PubMed Central

13 September 2017

Ferdinando De Vita

8

1 reference

Europe PubMed Central

13 September 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

71

1 reference

Europe PubMed Central

13 September 2017

283-290

1 reference

Europe PubMed Central

13 September 2017

3

1 reference

Europe PubMed Central

13 September 2017

Roles of CHOP/GADD153 in endoplasmic reticulum stress

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Overview of cell death signaling pathways

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Targeting the cell death-survival equation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

A trip to the ER: coping with stress

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

EGFR antagonists in cancer treatment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Approval summary for bortezomib for injection in the treatment of multiple myeloma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Proteasome inhibitor, bortezomib, for myeloma and lymphoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

The potential of proteasome inhibitors in cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.LUNGCAN.2010.06.005

Identifiers

10.1016/J.LUNGCAN.2010.06.005

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39682105&oldid=2043535971"